Search clinical trials for: The GLP-1 receptor agonist users

Total 1360 results

University of Mississippi Medical Center

Recruiting

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Diabetes Mellitus, Type 2 | Osteoporosis, Postmenopausal

United States
GlaxoSmithKline

Completed

Glucagon-like Peptide (GLP) Utilization and Safety

Diabetes Mellitus, Type 2
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
University of Missouri-Columbia
American Society for Metabolic and Bariatric Surgery

Recruiting

Impact GLP-1 Agonists Following Bariatric

Hypertension | Diabetes Mellitus | Metabolic Syndrome | Morbid Obesity | Obstructive Sleep Apnea of Adult

United States
Dasman Diabetes Institute

Recruiting

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Diabetes Mellitus, Type 2

Kuwait
King's College London

Recruiting

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

Obesity | Diabetes Mellitus | Mental Health Issue

United Kingdom
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Completed

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

Diabetes Mellitus, Type 2

Italy
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Completed

Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

Glucose Metabolism Disorders

Denmark
Jose Seijas Amigo

Completed

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. (SEVERAL)

Quality of Life | Diabetes Mellitus, Type 2 | Weight Loss | Safety Issues

Spain
Zealand Pharma
Profil Institut für Stoffwechselforschung GmbH

Recruiting

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Safety and Tolerability

Germany
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Completed

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Glucose Metabolism Disorders

Denmark
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Treating PCOS With Semaglutide vs Active Lifestyle Intervention (TEAL)

PCOS | NAFLD | Adolescent Obesity

United States
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Type 2 Diabetes Mellitus | Susceptibility, Genetic

China
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
PegBio Co., Ltd.

Completed

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects (PB119)

Type 2 Diabetes Mellitus (T2DM)

China
PegBio Co., Ltd.

Completed

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Type 2 Diabetes Mellitus (T2DM)

China
LMC Diabetes & Endocrinology Ltd.
Novo Nordisk Canada Inc.

Completed

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Chronic Kidney Diseases | Type 2 Diabetes

Canada
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute

Recruiting

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD)

Type2Diabetes | ASCVD

United States
Zydus Lifesciences Limited

Completed

A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers (ZYD1)

Type 2 Diabetes Mellitus

India
Nanjing First Hospital, Nanjing Medical University

Recruiting

The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

Type 2 Diabetes Mellitus

China
Radboud University Medical Center
Rijnstate Hospital

Recruiting

Visualizing Beta Cells After Bariatric Surgery (GLP1-bar)

Type 2 Diabetes Mellitus

Netherlands
University of Chicago

Completed

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Monogenic Diabetes

United States
Brigham and Women's Hospital

Unknown

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Diabetes Mellitus, Type 2

United States
University Hospital, Gentofte, Copenhagen
University of Copenhagen; Steno Diabetes Center Copenhagen

Completed

The Effect of GIP(3-30)NH2 (GA-10)

Endocrine - Other

Denmark
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
Centre Hospitalier Universitaire Dijon

Completed

Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging (LICAS-MR)

Type II Diabetes

France
University of Padova

Completed

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Type 2 Diabetes

Italy
University of Surrey
Sanofi

Completed

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

Type 2 Diabetes

United Kingdom
Second Xiangya Hospital of Central South University
Guangdong Provincial People's Hospital; The First Affiliated Hospital of Henan... and other collaborators

Recruiting

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Diabetes Mellitus, Type 2 | Overweight or Obesity

China
The Affiliated Hospital of Xuzhou Medical University

Completed

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Type 2 Diabetic Nephropathy

China
Western University, Canada
Unity Health Toronto; Lawson Health Research Institute; Queen Elizabeth II Health...

Not yet recruiting

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

Obesity | Chronic Kidney Disease

Canada
xiaolong zhao
Shanghai Zhongshan Hospital; Second Affiliated Hospital of Soochow University; Taizhou Hospital and other collaborators

Unknown

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy (T2DMRS)

Type 2 Diabetes

China
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; Massachusetts General Hospital; University of Missouri-Columbia and other collaborators

Recruiting

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes (BESTMED)

Diabetes Mellitus, Type 2

United States
Diabeteszentrum Bad Lauterberg im Harz

Completed

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Type 2 Diabetes

Germany
University of Tartu

Completed

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Type 2 Diabetes

Estonia
University of Southern California
The Leona M. and Harry B. Helmsley Charitable Trust

Completed

Specialized Technology Education for Pumps & Pens in Underserved Populations With Diabetes (STEPP-UP)

Type1diabetes

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Glioma

United States
Bayer

Active, not recruiting

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice (FINEGUST)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Japan, Spain, Netherlands, United Kingdom, Denmark, United States
Shanghai 10th People's Hospital

Completed

GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome

China
RenJi Hospital

Completed

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

Polycystic Ovary Syndrome

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
AstraZeneca

Not yet recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED)

Pancreatic Cancer
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy (KIN-ATTACK-FMF)

FMF

France
Acorda Therapeutics

Completed

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Migraine

United States
Lesaffre International
BioFortis; Soladis

Terminated

Bioavailability Study of Folate in Healthy Subjects

Healthy

France
University of California, San Francisco

Completed

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Type 2 Diabetes Mellitus

United States
University Hospital, Gentofte, Copenhagen
University of Copenhagen; Hvidovre University Hospital; Glostrup University Hospital...

Unknown

Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
University of California, Los Angeles

Recruiting

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Obesity

United States

Search clinical trials for: The GLP-1 receptor agonist users

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations